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Ischemia in the immature brain is an important cause of neonatal seizures. Temporal
evolution of acquired neonatal seizures and their response to anticonvulsants are
of great interest, given the unreliability of the clinical correlates and poor efficacy
of first-line anti-seizure drugs. The expression and function of the electroneutral
chloride co-transporters KCC2 and NKCC1 influence the anti-seizure efficacy of
GABAA-agonists. To investigate ischemia-induced seizure susceptibility and efficacy
of the GABAA-agonist phenobarbital (PB), with NKCC1 antagonist bumetanide (BTN)
as an adjunct treatment, we utilized permanent unilateral carotid-ligation to produce
acute ischemic-seizures in post-natal day 7, 10, and 12 CD1 mice. Immediate
post-ligation video-electroencephalograms (EEGs) quantitatively evaluated baseline and
post-treatment seizure burdens. Brains were examined for stroke-injury and western blot
analyses to evaluate the expression of KCC2 and NKCC1. Severity of acute ischemic
seizures post-ligation was highest at P7. PB was an efficacious anti-seizure agent
at P10 and P12, but not at P7. BTN failed as an adjunct, at all ages tested and
significantly blunted PB-efficacy at P10. Significant acute post-ischemic downregulation
of KCC2 was detected at all ages. At P7, males displayed higher age-dependent seizure
susceptibility, associated with a significant developmental lag in their KCC2 expression.
This study established a novel neonatal mouse model of PB-resistant seizures that
demonstrates age/sex-dependent susceptibility. The age-dependent profile of KCC2
expression and its post-insult downregulation may underlie the PB-resistance reported in
this model. Blocking NKCC1 with low-dose BTN following PB treatment failed to improve
PB-efficacy.
Keywords: neonatal seizures, ischemia, KCC2, NKCC1, phenobarbital, bumetanide
Abbreviations: PB, Phenobarbital; BTN, Bumetanide; GABA, gamma-aminobutyric acid; EEG, electroencephalogram; HIE,
hypoxic ischemic encephalopathy; AED, anti-epileptic drug.
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Introduction
Neonatal seizures are the most frequent clinical manifestation
of central nervous system dysfunction in newborns, with an
incidence of 1.5–3.5/1000 in term newborns, and an incidence
as high as 10–130/1000 in preterm newborns (Evans and
Levene, 1998; Volpe, 2001; Clancy, 2006; Tekgul et al., 2006;
Bassan et al., 2008). Ischemia is a major cause of neonatal
seizures (Lynch et al., 2002) and first-line anticonvulsant
pharmacotherapy by commonly used anti-seizure drugs like PB
often proves insufficient (Hunt and Inder, 2005; Kossoff, 2011).
Both animal-model and human studies suggest that neonatal
seizures themselves may worsen brain injury, decrease the
threshold for subsequent seizures, and result in poor long-term
neurological co-morbidities (Lombroso, 1996, 2007;Wirrell et al.,
2001; Holmes, 2002; Clancy, 2006). Electroclinical dissociation is
now a fairly well-accepted concept in human neonates, wherein
GABA agonists are able to block the clinical manifestations of
seizures; however, as displayed with electrographic monitoring,
the brain continues to seize (Weiner et al., 1991; Scher, 2003;
Staley, 2006; Evans et al., 2007; Rakhade and Jensen, 2009).
Early in development, the depolarizing GABAAergic signaling
that is instrumental in normal neuronal differentiation and
migration has been shown to be responsible for the inefficacy
of GABAA agonists like PB, as an anti-seizure agent (Dzhala
et al., 2008, 2010; Kahle et al., 2008). Therefore, cation chloride
co-transporters, specifically NKCC1 and KCC2, could be used
as potential targets for novel anti-seizure and anti-epileptogenic
treatments (Loscher et al., 2013). NKCC1 is expressed in neurons
and astrocytes throughout the brain, systemically in the kidney
and inner hair cells of the ear (Lytle et al., 1995; Delpire et al.,
1999; Flagella et al., 1999), and is robustly involved in early neural
development (Pfeffer et al., 2009). The co-transporter KCC2 is
CNS-specific predominantly in neurons and has a developmental
expression profile that increases exponentially during the third
trimester and continues to increase post-natally with advancing
age (Dzhala et al., 2005; Kaila et al., 2014).
BTN, a potent NKCC1 antagonist that has been used as
a diuretic in newborns, was also shown to be effective in
reducing kainic acid-induced and hypoxic seizures in neonatal
animals by blocking NKCC1 (Dzhala et al., 2008; Cleary et al.,
2013) especially when used in combination with PB (Dzhala
et al., 2008). BTN later became the focus of clinical trials
to test its efficacy in seizing neonates with hypoxic ischemic
encephalopathy (HIE; BTN clinical trial in Europe, 20091; BTN
clinical trial in USA, 20092). However in pre-clinical studies, the
anti-seizure effect of BTN has been shown to depend on the
experimental model. BTN enhanced, suppressed, or had no effect
on paroxysmal activity in vitro in different models, none of which
modeled ischemia (Kilb et al., 2007; Vanhatalo et al., 2009; Kang
and Kadam, 2014; Puskarjov et al., 2014b). Additionally, a recent
study showed that kainic acid-induced seizures increased the
surface expression of KCC2 (Khirug et al., 2010), shifting E(GABA)
close to the adult levels. However, under ischemic conditions, a
1BTN clinical trial in Europe (2009) http://cordis.europa.eu/projects/241479.
2BTN clinical trial in USA (2009) http://clinicaltrials.gov/ct2/show/
NCT00830531?term=bumetanide&rank=1.
substantial neuron-specific downregulation of KCC2 expression
has been reported (Rivera, 2004; Jaenisch et al., 2010), which was
also detected in our mouse model of neonatal ischemia. Such
discordant model-specificity in the post-injury KCC2 expression
may significantly alter the efficacy of drugs that depend on the
Cl− gradient for their anti-seizure effects. In new developments,
the European clinical trial has recently been terminated for
non-efficacy of BTN with associated ototoxicity following HIE
induced seizures in neonates (Pressler et al., 2015).
This study utilized cerebral ischemia alone to induce acute
ischemic seizures in the CD1 mouse strain, and investigated
the following: (1) Quantitative analyses of EEG recordings of
early post-stroke events at P7, P10, and P12 to determine the
acute age-dependent seizure susceptibilities and seizure burdens
following ischemia. (2) Response of the ischemic seizures to
standard anti-seizure agent PB, as well as novel agent BTN
at doses similar to the clinical trials, to evaluate for the first
time, the effect of the NKCC1 blocker BTN, as an adjunct
in a model of acute ischemic seizures. (3) Effect of neonatal
ischemia on the developmental expression profile of KCC2 and
NKCC1.
Methods
Experimental Design
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Johns Hopkins University (Permit Number:
A3272-01). All surgery was performed under isoflurane general
anesthesia, and all efforts were made to minimize suffering.
All litters of CD1 mice were purchased from Charles River
Laboratories Inc. (Wilmington, MA). Newly born litters of pups
arrived at post-natal 3 or 4 days old, and were allowed to
acclimate. Animals were housed in polycarbonate cages on a 12 h
light-dark cycle and food provided ad libitum. Ninety two pups
from 12 litters were included in the video-EEG study (n = 48
male and n = 44 female). The susceptibility to ischemic seizures
was tested at 3 developmental ages i.e., 7, 10, and 12 days old CD1
pups (n = 80 ligated and 12 shams). The experimental paradigm
is depicted in Figure 1. The pups underwent permanent ligation
and sham surgeries followed by 3 h of EEG recording each, as
described in methods (total pups = 92 of which ligates P7 = 29,
P10 = 24, and P12 = 27 and sham P7 = 5, P10 = 4, and P12 =
3; see Supplementary Table 1). From the ligated group of pups
(total n = 80), the ligated-control pups also underwent 3 h EEG
recordings to evaluate natural progression of ischemic seizure
burden over the duration of treatment efficacy evaluated in this
study (total pups n/n = 26/80, P7 = 8, P10 = 9, and P12 = 9).
Following ligation, the ligated-treated group of pups [total pups
n/n = 52/80; P7 = 20 (13 male and 7 female); P10 = 16 (8 male
and 8 female), and P12 = 18 (9 male and 9 female)] were used
to evaluate every baseline EEG (i.e., 1st h of recording) that was
then compared to post-PB (2nd h of recording) and post-BTN
(3rd h of recording) EEGs. Since the severity of stroke-injury and
seizure varies between pups, the baseline EEG of each pup served
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FIGURE 1 | (A) Representative video-frame from a ligated pup having an ischemic tonic-clonic seizure. (B,C) Schematics of the time-line and experimental design.
as an important internal control. Additionally, since the exact
time-point of onset for ischemia in human neonates is not known
and may not be a single massive event, the 1 h of non-treatment
also served as an important delay expected in the treatment of
neonatal seizures that are detected hours after stroke in humans.
There was an age-dependent mortality associated with survival to
age P18 following the ischemic seizures in this study [i.e., 8 out of
29 pups at P7 (2 males and 6 females); 6 out of 24 pups at P10
(3 males and 3 females); and none at P12].
Surgical Procedure for Ischemic Insult and
Electrode Implantation
Animals were anesthetized with 2% isoflurane. The right
common carotid artery was permanently double-ligated with
6-0 surgisilk and the outer skin closed with 6-0 monofilament
nylon to induce ischemia (i.e., ischemia was induced by
unilateral common carotid-ligation alone. Unlike other rat
models commonly used for neonatal stroke, no global hypoxia
is needed to induce acute ischemic seizures). Since the ligated
carotid is not transected in our model, the intact pulsating
carotid artery with silk ligatures can lead to reperfusion over time
in this model. The constrictive efficacy (which drops cerebral
perfusion to 40% or less) of the silk ligatures is known to
diminish, due to the loss of their tensile strength in-vivo against
the pulsating artery as a function of time (Kadam et al., 2008a).
Sham-control animals were treated identically except for the
carotid ligation, and did not seize (Supplementary Figure 2A).
The animals were then implanted with three sub-dermal EEG
electrodes (1 recording, 1 reference, and 1 ground) on the skull
overlying the parietal cortex using bregma as a reference. Scalp
wire electrodes made for sub-dermal use in humans (IVES EEG;
Model # SWE-L25—MA, USA) were implanted, sub-dermally
fixed with adhesive, in the pups. The suggested spacing for
human scalp electrodes is 5–8mm, which allows for optimal
acquisition of EEG signal from mouse brains (Freeman et al.,
2003). In this study, the recording and reference electrodes were
implanted less than 1 cm apart. Pups were then allowed to recover
from anesthesia in a 36◦C isothermal chamber for 3 h recording
of video-EEG (Figure 1). At the end of the recording session, the
pups were returned to the dams after removal of the sub-dermal
electrodes and application of local anesthetic medication.
In Vivo Synchronous Video-EEG Recording
After the completion of the surgical procedures (i.e., ligation
+ electrode implantation; 8min + 8min ∼ 16min total),
the EEG recordings were initiated after the pups recovered
from anesthesia. Bumetanide [0.1–0.2mg/kg dissolved in
100% alcohol, aliquoted, and stored at −20◦C; protocol
similar to previous study (Dzhala et al., 2005)], phenobarbital
(25mg/kg dissolved in 0.9% sodium chloride, made on the
day of experiment), or 0.9% sodium chloride was injected
intraperitoneally (IP) after baseline post-stroke EEGs were
recorded (Figure 1C). Since these experiments were also
designed to test BTN-efficacy as an adjunct therapy to PB
(based on the currently recruiting clinical trials), ligated mice
underwent one of two regimens: (1) Treatment with saline only
at 1 h and 2 h post-surgery; (2) Treatment with PB at 1 h and
BTN at 2 h post-surgery. The treatment regimen of BTN before
PB or BTN without PB was not relevant to this translational
design. Pharmacokinetics of PB and BTN additionally supports
our treatment regimen, because PB is a long acting drug even
in immature rodents [half-life ∼15 h (Markowitz et al., 2010)
whereas BTN has a very short half-life of <30min (Cleary et al.,
2013)]. Data acquisition was done using PAL-8400 software with
synchronous video capture (Pinnacle Technology Inc.). The data
acquisition and conditioning system had a 14-bit resolution,
sampling rates of 500Hz, high pass filters of 0.5Hz, and low pass
filters of 1 kHz. The files were stored in.EDF format and scored in
real time using the review and scoring software package. Manual
scoring of all EEG files was done blinded to treatment protocols
by simultaneously scoring EEG traces and the synchronous
video in real time. Seizure burden scoring was done on EEG
with sampling rates of 400Hz that had a pre-amplifier gain of
100. The filters of 1Hz high-pass and 60Hz low-pass were used
to remove ambient noise, and the binning was done in 10 s
intervals. Seizures were defined as electrographic ictal events
that consisted of rhythmic spikes of high amplitude, diffuse
peak frequency of ≥7-8Hz (i.e., peak frequency detected by
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automated spectral power analysis) lasting more than 6 s. Short
duration burst activity lasting <6 s (brief runs of epileptiform
discharge) was not included for seizure burden calculations in
this study (Supplementary Figure 1).
Behavioral Seizure Scoring After EEG Seizure
Detection
After an EEG seizure was detected, its time and duration of
occurrence were noted, and the synchronous behavioral activity
recorded on video was scored according to a seizure rating
scale modified for mouse pups from a previously reported
scale used for adult mice (Morrison et al., 1996; Kadam et al.,
2008b). Behavioral seizures recorded on video for EEG-identified
seizures (Figures 2A–C; Supplementary Figure 1) were scored
as follows: 0 = motionless/inactive; 1 = flexor spasms; 2
= jittery movements; 3 = repetitive grooming/scratching,
circling toward side of ischemia, with head bobbing
(Supplementary Video 1); 4 = limb clonus, unstable posture;
5 = mice that exhibited level four behaviors for >30 s or
with loss of posture (Supplementary Video 2); and 6 =
severe tonic-clonic behavior with inability to regain loss of
posture. After video-EEG recording, the mice were returned
to the dam and littermates. Electrographic seizures associated
with grade 0–2 behaviors were grouped as non-convulsive
seizures and grade 3–6 behaviors were graded as convulsive
seizures.
Histology
All animals were anesthetized with chloral hydrate (90mg/ml; IP)
before being transcardially perfused with saline and 10% formalin
in phosphate buffer (pH 7.4). The whole brain was removed and
submerged in the same fixative. The brains were cryoprotected by
first immersing in 15% sucrose for 24 h, followed by 30% sucrose
for 24 h. The brains were rapidly frozen using dry ice and placed
FIGURE 2 | Age-dependent seizure burden and PB-efficacy. (A–C)
Representative electrographic traces of ischemic seizures recorded with
sub-dermal scalp electrodes at P7, P10, and P12 and their associated
behavioral grades on video. Arrowheads show the start and end of ictal
events. (D–F) EEG seizure burden, mean number of ictal events, and
ictal durations in ligated-controls that received saline injections at each
hour after ligation. Seizure burden after ischemia at baseline recording
was highest at P7, and was significantly more severe than at P10
(p = 0.01) and P12 (p = 0.03): pairwise t-test (G–I). Electrographic
seizure burden, mean number of ictal events, and ictal durations in
ligated-treated mice that received PB (1 h post-ligation) and BTN (2 h
post-ligation; adjunct to PB). PB (25mg/kg; IP) was inefficacious as an
anti-seizure agent at P7. At the same loading dose, PB was significantly
efficacious as an anti-seizure agent at P10 and P12. BTN as an
adjunct failed to improve PB-efficacy at any age tested, and significantly
blunted PB-efficacy at P10. PB-efficacy at P10 and P12 (G) was due
to significant reduction in mean number of ictal events (H). Ictal
durations were not significantly different at any age tested (I).
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in−80◦C storage. Coronal brain sections (40µm thick) were cut
on a cryostat in serial order to create 5 series of sections and
mounted on super frost plus glass slides. One series of sections
from the EEG recorded pups was cresyl violet (CV) stained to
quantitate ischemia injury using a previously described method
of computer-assisted comparison of brain tissue area (Kadam
et al., 2008b) in ipsilateral vs. contralateral hemispheres of fixed
CV stainedmouse brain sections (i.e., BasicMCID). Stroke injury
severities were quantitated at P18 for all brains processed for CV
(n = 49/80; P7 = 15, P10 = 15, and P12 = 19) to compare
differences in infarct injury evolution between age groups. The
remaining brains from study were fresh frozen for western blot
analysis.
Immunohistochemistry (IHC) with triple labeling: Serial
sections from frontal and parietal cortex and dorsal hippocampi
from a separate cohort of naïve CD1 pups aged P3 to P22
were labeled with neuronal marker NeuN (1:100, Chemicon
International; Catalog # MAB377) and then processed for double
labeling with NKCC1 [1:100, Chemicon International: detecting
22 amino acid peptide sequence near the C-terminus (exon
21); Catalog # AB3560P] and KCC2 (1:200, Upstate: targeting
N-terminal His-tag fusion protein corresponding to residues
932–1043; Catalog # 07-432). The NKCC1 antibody used in this
study is similar to those used in related published literature and is
incapable of detecting NKCC1b, due to the post-transcriptional
splicing of exon 21 that overlaps with the targeted epitope site
for the antibody (Plotkin, 1997; Dzhala et al., 2005; Aronica,
2007). Currently no pan-NKCC1 (i.e., splice isoforms a and b)
antibodies are available. To block nonspecific binding, sections
were first incubated for 1 h at room temperature (RT) in a
solution containing 0.2% Triton X-100 and 10% normal goat
serum in PBS (Invitrogen). The sections were incubated with
primary antibodies overnight at 4◦C. After 3 × 10min wash
in PBS, slides were incubated at RT with secondary antibodies
(Alexa flour 488 and 594). After secondary antibody incubation,
sections were washed 3 × 10min in PBS and cover-slipped with
an anti-fade medium for further image processing (Axiovision,
Zeiss). Confocal microscopy of FV 1000 system with Olympus
IX81 inverted microscope stand was used to acquire images of
immuno-stained sections. Z-stack images with 5 um step-size
for bilateral cortices was obtained from coronal sections cut at
40µm thickness. The Z-stacks were fused to obtain the final
images.
Western Blots
All animals for immunochemical characterizations were
anesthetized with chloral hydrate (90mg/ml; IP) before being
transcardially perfused with ice-cold saline. The whole fresh
brains were removed, separated into left and right cerebral
hemispheres and frozen in liquid nitrogen and stored at −80◦C
in preparation for further processing. Brain tissue homogenates
were made and suspended in RIPA buffer containing one
Complete Mini, Ethylenediaminetetraacetic acid (EDTA)-free
protease inhibitor cocktail tablet (Roche Indianapolis; Catalog
# 04693159001) per 10mL of buffer. Total protein amounts
were measured using the Bradford protein assay (Bio-Rad)
and samples diluted for equal amounts of protein in each
sample. Fifty micrograms of protein samples were run on 4–12%
gradient SDS gels (Bio-Rad) and transferred onto polyvinylidene
difluoride (PVDF) membranes. Membranes were blocked for
1 h in odyssey buffer before overnight incubation in primary
antibodies, NKCC1 and KCC2. Blots were then incubated for
1 h in secondary antibodies (Licor; IR Dye 800CW Donkey
anti-Rabbit IgG: Product # 926-32213 and IR Dye 680LT Goat
anti-Mouse IgG: Product # 926-68070). Protein bands were
visualized by chemiluminescence, using the Odyssey infrared
imaging system 2.1 (LI-COR biosciences). The optical density
of each sample was normalized to the level of expression of
the actin run on each blot, for each antibody for statistical
analysis. KCC2 and NKCC1 expression profiles in ipsilateral
ischemic hemispheres were normalized to contralateral non-
ischemic hemispheres in the same brain homogenized samples
to compare differential effects of ischemic injury in the
model.
Statistics
Group means for seizure severity between treated and control
mice were analyzed with independent sample student’s t-tests.
Treatment efficacy following PB+BTN administration for seizure
burdens was analyzed using repeated measures One-Way
ANOVAs followed by pairwise t-tests. Mauchly’s test was used
to confirm the equal variances of the differences detected in
repeated measures ANOVA, which is known for testing a
statistical assumption of sphericity. No significance detected in
Mauchly’s test indicates that the assumption of sphericity for
the relevant F-test in repeated measure ANOVA is not violated
(Mauchly, 1940). Non-parametric correlations among severities
of infarct lesion, seizure counts, and seizure frequency (both
electrographic and behavioral) were assessed by Spearman’s
test. Differences with p < 0.05 were considered statistically
significant.
Results
Age-dependent Susceptibility to Ischemic
Seizures and Response to Anticonvulsants
EEG recordings in the post-ligation period (Figure 2) revealed
ictal events along with interictal spikes and non-convulsive
epileptiform discharges between ictal events (i.e., short duration
bursts lasting 2–5 s). Ictal events on EEG (i.e., lasting >6 s)
associated with video correlates where pup was seen to be
motionless or inactive (grade 0) or ictal events with behavioral
correlates of grade 1 or 2 (i.e., scale 1–6; Morrison et al.,
1996) were graded as non-convulsive (since these behaviors
are also seen in naïve littermates), as described in methods.
The baseline acute ischemic seizures recorded in the 1st post-
ischemic hour were significantly more severe at P7 (ligated
control and ligation-treated group pooled) compared to P10
and P12 (Figures 2D,G, black bars, p < 0.0001 between P7
vs. P10 and P7 vs. P12). The ligated-control group of P10
pups showed a significant decrease in the number of ictal
events in the 3rd h of EEG recording (Figure 2E) not seen
at P12.
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Ligated-treated pups using the same 3 h recording paradigm
with PB (25mg/kg) treatment at 1 h post-ligation and BTN
(0.1–0.2mg/kg) as an adjunct 2 h post-ligation followed similar
trends for baseline EEG severities as the ligated-control group
(Figures 2G–I, black bars, Supplementary Figure 3). However,
interesting age-dependent drug efficacies were detected within
the treated group of pups. At P7, PB and BTN both failed to
have any significant anti-seizure effect on total time spent seizing
on EEG (Figure 2G, Supplementary Figure 3). PB, however, did
modulate the ischemic seizures by significantly reducing the
number of ictal events in the 2nd h recording (Figure 2H, p =
0.04). The lack of overall PB-efficacy as an anti-seizure therapy
resulted from a sustained increase in the duration of post-
treatment ictal events (Figure 2I) that was not seen in the ligated-
control group (Figure 2F). Adjunct BTN administration did not
improve PB-efficacy, and the longer ictal durations persisted
at P7. In contrast, at P10, PB administration 1 h after ligation,
significantly reduced the seizure burden by 61% (Figure 2G,
gray bar; Supplementary Figure 3) by significantly reducing the
number of ictal events (Figure 2H, gray bar). No significant
effect on the duration of the ictal events was detected (Figure 2I,
gray bar). Follow-on BTN administration, failed to improve
PB-efficacy, and additionally PB-induced seizure suppression
was lost at P10 (Figure 2G; Supplementary Figures 3, 6). This
significant aggravation of seizures was driven by an increase in
the number of ictal events (Figure 2H; Supplementary Figure 6)
following BTN IP injection. At P12, post-PB seizure suppressions
were similarly effective compared to P10. PB treatment after
1st h significantly reduced the seizure burden by 64% due to
a significant reduction in overall number of ictal events. BTN
again failed to act as an effective adjuvant as it did not improve
PB-efficacy (Figure 2G; Supplementary Figure 6).
When ligated-control and ligated-treated groups were directly
compared to each other by pairwise t-tests, no significant
difference was detected among the different groups for baseline
seizure burden at P7 (p = 0.67, black bars Figure 2D compared
to Figure 2G), P10 (p = 0.9, black bars Figure 2D compared
to Figure 2G), or at P12 (p = 0.1, black bars Figure 2D
compared to Figure 2G). Additionally, at P7, post-treatment
seizure burdens in ligated-treated group were not significantly
different from the ligated-control group in the 2nd and 3rd
h of recordings [P = 0.6 (gray bars) and 0.6 (white bars),
respectively]. In contrast, at P10 and P12, post-PB (i.e., 2nd h)
seizure burden was significantly lower in ligated-treated group
than in the ligated-control group during the same period (p =
0.007 and 0.03, respectively, gray bars).
Repeated measures ANOVAs using a within subjects design
for efficacious drug effects using the PB+BTN protocol in the
ligation-treated group were also evaluated. At P7, Mauchly’s test
for sphericity was not significant (p = 0.2) and within-subject
drug effect was not significant (df = 2, F = 0.62, and p = 0.55).
At P10, Mauchly’s test for sphericity was significant (p = 0.02)
and within-subjects drug effect was also significant (df = 2,
F = 6.54, and p = 0.01). The within-subjects contrast showed
that the linear drug effect was not significant, but the quadratic
drug effect was significant (p = 0.01). At P12, Mauchly’s test for
sphericity was not significant (p = 0.9) and within subject drug
effect was not significant (df = 2, F = 3.690, and p = 0.06). At
P12, the within-subjects contrast was not significant for either the
linear or quadratic drug effect. In summary, PBwas a significantly
efficacious anti-seizure agent both at P10 and P12 when evaluated
by within-group pairwise t-tests and by independent sample
t-tests compared to the ligated-control group. However at P7,
PB+BTN failed to act as an efficacious anti-seizure therapy. At
all three ages evaluated, BTN failed to improve PB-efficacy, but
significantly blunted the PB-subdued ischemic seizures at P10.
The overall lack of BTN-efficacy in the model and PB inefficacy
at P7 could not be attributed to the clustering of seizures (see
Supplementary Figure 6).
Non-convulsive vs. Convulsive Seizures at P7,
P10, and P12
The unique advantage of synchronous video-EEG in this study
was its ability to identify and quantitate the non-convulsive
seizures for the entire data set. Similar to humans, neonatal
seizures in rodents can be difficult to identify by behavioral
parameters alone (Cuaycong et al., 2011). To evaluate if the
treatment efficacy was different for seizures graded as 0–2 (i.e.,
electrographic—ranging from inactive to behavioral correlates
associated with movements not overtly convulsive—see
Methods) and 3–6 (i.e., convulsive), the data were grouped
by these seizure scores as the sum of [grade of the seizure X
count] in each epoch of the recording (Figure 3). Electrographic
seizures were detected at every age investigated in this study,
and were not significantly different for the probability of
occurrence during the baseline EEG (i.e., early seizures in
immediate post-stroke period; Figure 3A). Convulsive seizures
showed an age-dependent decrease of occurrences for baseline
EEG (Figure 3B); however, this difference was not significant.
Repeated measures ANOVAs for PB+BTN treatment efficacy
showed that the within-subjects drug effects were significantly
efficacious for electrographic seizures at P10 and P12 but not at
P7 (P7: df = 2, F = 3.025, p = 0.07, P10: df = 2, F = 5.224,
p = 0.03, and P12: df = 2, F = 9.144, p = 0.004). However, for
grade 3–6 seizures, the within-subjects drug effects for PB+BTN
efficacy were not significant at P7 and P12 but significant at P10
(i.e., P7: df = 2, F = 1.224, p = 0.3, P10: df = 2, F = 6.604,
p = 0.02, and P12: df = 2, F = 3.262, p = 0.07). For the pairwise
t-tests, PB significantly dropped the scores of both electrographic
and convulsive seizures at P10 and P12, but failed to curb either
at P7. In contrast, follow-on BTN treatment did not add any
significant therapeutic benefit on electrographic seizure scores at
any age and the post-BTN increase of seizure burden at P10 was
driven by significant increase in the occurrence of convulsive
seizures following effective PB-driven seizure suppression.
Correlation of Baseline Seizure Severity to
Post-PB Efficacy as a Function of Post-natal Age
To evaluate whether the severity of seizure burden during
baseline EEG with no drug on board contributed to the PB-
efficacy given 1 h later, correlations between the numbers of ictal
events during baseline recording and during post-PB recording
were evaluated in the ligated-treated group (Figure 4). At P7,
there was a significant positive correlation between the number
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FIGURE 3 | Behavioral correlates of EEG seizures and
PB-efficacy. (A) Electrographic seizures (grade 0–2) occurred at all
ages tested, and responded well to PB treatment at P10 and
P12. This response was not significant at P7 (repeated measures
ANOVA). (B) Likewise, the convulsive seizures (grades 3–6) also
showed significant PB-efficacy at P10 and P12 only with significant
BTN aggravation of the convulsive seizures at P10 (repeated
measures ANOVA). Gray * = P10, # = P12, represent significant
p-values for pairwise t-tests. Therefore, PB failed to block either
electrographic or convulsive seizures at P7.
of ictal events in the 1st and 2nd post-PB treatment hours
(Figure 4A; p = 0.02). Since PB was inefficacious at P7,
this indicated that PB had no effect on overall post-PB ictal
counts in each pup. Interestingly, correlations at P10 after PB-
treatment compared to baseline showed a significantly stronger
positive correlation than at P7 (Figure 4B; p = 0.001). Since PB
was an efficacious anti-seizure agent at P10, this may indicate
that the anti-seizure efficacy of PB was dependent on baseline
seizure burdens (i.e., if initial seizure burden was high, follow-
on post-treatment seizure burden remained high). Additionally,
Figure 4B, group brackets representing low and high baseline
seizure burdens indicate that PB was very efficacious in subduing
all low seizure burdens (i.e., ≤250 s). This is supported by
additional correlations run for baseline vs. post-PB seizure
burdens which showed that low baseline seizure burdens and
PB efficacy at P10 were not significant (for baseline seizure
burden ≤250 s; r = 0.35, p = 0.39) but high baseline seizure
burdens at P10 showed significant positive correlations to their
post-PB seizure burdens (for baseline seizure burden >250 s;
r = 0.61, p = 0.03). In contrast, at P12, baselines vs. post-
PB correlations were not significant (Figure 4C). Since PB was
highly efficacious at P12, this illustrates a strong anti-seizure
efficacy of PB, irrespective of baseline seizure burdens.
Age-dependent Stroke Injury
Stroke injury severities were quantitated at P18 for all brains
processed for histology (n = 49; P7 = 15, P10 = 15, and P12
= 19) and the remaining brains from study were fresh frozen for
western blot analysis. Ligations at P7 did not result in a cystic
infarct injury when evaluated at P18 (Figure 5A). Although the
P7 ligated brains, when harvested for western blot analysis at
6–8 h after ligation showed edema of the ipsilateral hemisphere,
no measurable atrophy was detected when P7 ligated brains
were harvested and processed for histology at P18 (Figure 5).
Microscopic examination also did not reveal obvious cell death
in the watershed zones. Post-stroke diffuse cell death cannot be
ruled out in the P7 brains however; compared to the P10 and P12
ligated pups, injury at P7 in CD1 ischemic pups may have white
matter injury, which was not evaluated in this study (Fatemi
et al., 2011). Overall, P7 pups showed a significant resistance to
necrotic infarcts in the middle cerebral artery perfusion territory
detected at P10 and P12 (Figures 5A,B; p = 0.005 P7 vs. P10
for both hemispheric and hippocampal atrophy and p < 0.0001
P7 vs. P12 for both hemispheric and hippocampal atrophy).
The mean hemispheric and hippocampal atrophy in P10 were
not significantly different from those in P12 (p = 0.3 and 0.1,
respectively).
To determine whether injury severity evaluated at P18
correlated with the seizure severity in the 1st 3 h after
ischemic insult at the three ages examined, hippocampal
and hemispheric atrophies were compared to the time spent
seizing on EEG. No significant correlations were detected at
any age. Additionally, significant positive correlations between
hemispheric to hippocampal atrophy were detected for the P12
(p = 0.008) ligated group at P18, which has been reported
previously for ligated-control P12 mice at P40 (Kadam et al.,
2008b). Similar correlations were not detected for the P10 ligated-
treated group. No significant correlations were detected between
the severities of ischemic seizure burdens at baseline and the
severity of the ischemic injury at P18, in either the P10 or P12
pups. No significant sex differences in injury severity were noted
at P10 and P12 either. Since stroke injuries evolve over time,
injury assessments at longer survival time-points may be more
predictive of initial seizure burdens.
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 May 2015 | Volume 9 | Article 173
Kang et al. Neonatal seizures and Cl− co-transporters
FIGURE 4 | Ictal events vs. PB-efficacy. (A–C) Correlations of the number
of ictal events before treatment (i.e., during baseline EEG recording) to the
number of ictal events post-PB treatment at P7, P10, and P12. Brackets in
(B,C) show the difference in the PB-efficacy at P10 vs. P12. Post-PB seizure
suppression at P12 was consistently significant and uniform regardless of
baseline seizure severities (p = 0.09). In contrast, at P10, PB-efficacy was
significantly dependent on the baseline seizure severity (i.e., better efficacy
with lower baseline seizure loads compared to higher baseline seizure loads).
Additional correlations run for baseline vs. post-PB seizure burdens showed
similar results (see brackets in B; first bracket ≤20 i vs. second bracket >20
ictal events); low baseline seizure burdens and PB-efficacy were not
significantly correlated (for baseline seizure burden ≤250 s; r = 0.35,
p = 0.39); high baseline seizure burdens showed significant positive
correlations to their post-PB seizure burdens (for baseline seizure burden
≤250 s; r = 0.61, p = 0.03). This may indicate the potential role of the number
of ictal events that have occurred before treatment on the efficacy of
anti-seizure agents at P10 (p = 0.001).
Age- and Sex-dependent Seizure Susceptibilities:
Is KCC2 a Major Player?
To establish an age-dependent expression profile for the CD1
mouse strain used in this model, we examined KCC2 and
NKCC1 expression in naïve pup brains in ages advancing
from P3 to P22 (Figure 6A and Supplementary Figure 4A). As
reported previously in both rodents and humans (Dzhala et al.,
2005), we saw an age-dependent increase in the expression
of KCC2 examined both by IHC and western blot analyses
(Figures 6A,B). In contrast, NKCC1 [i.e., detecting NKCC1a, the
non-dominant spice-isoform (see Methods Section—Histology)]
showed an age-dependent decrease using the same samples
(Supplementary Figures 4A,B). Additionally at P7, a sex-
dependent lag in the KCC2 expression levels was detected
in naïve males compared to the age-matched females, which
was not detected at older ages when examined up to the
age of P12 (Figure 6C). Similar sex-dependent maturational
lags have been previously reported for males (Nunez and
McCarthy, 2007; Perrot-Sinal et al., 2007; Galanopoulou, 2008;
McCarthy et al., 2012; Murguia-Castillo et al., 2013). No
sex-dependent maturational lags were detected with NKCC1
(Supplementary Figure 4C). These findings, in addition to the
higher susceptibility to ischemic seizures detected in P7 males
(see Figures 7A,B) may indicate KCC2 as the major player
underlying the age-dependent seizure susceptibility detected in
this model.
Sex-dependent Susceptibility to Ischemic
Seizures and Response to Anticonvulsants
When the baseline EEG scores (i.e., seizure burden in the 1st h
post-ligation) for both ligated-control and ligated-treated were
pooled to further analyze the effect of sex on the age-dependence
of seizure susceptibility, a One-Way ANOVA showed a
significance for males only. Post-hoc (Bonferroni) comparisons
showed P7 males to be significantly more susceptible to seizures
than either P10 (p = 0.04) or P12 (p = 0.01) males (Figure 7A,
Supplementary Figures 2B,C). No significant differences were
noted for females (Figure 7B). Based on this finding, future
studies need to address this sex and age-dependent ischemic-
seizure susceptibility when evaluating the efficacy of PB and BTN
treatment.
PB-resistant Ischemic Seizures and an Acute
Downregulation of KCC2 Expression
In this study, an acute post-ischemic downregulation of KCC2
expression was detected in the ipsilateral hemisphere compared
to the contralateral hemisphere beginning from a few hours
to 48 h after ischemia at all ages tested (Figures 8A–D). The
post-ischemic downregulation of KCC2 expression in ipsilateral
hemisphere was ∼45% compared to uninjured contralateral
hemisphere (Figure 8D; pairwise t-test, p = 0.0002). A trend
toward recovery from the downregulation was also detected in
the P7 age group at 96 h after ischemia (Figures 8A–D). Although
in humans NKCC1a represents a non-dominant isoform of
NKCC1 splice variant, the analogous expression profiles in
rodents are not known due to the current lack of a pan-
NKCC1 antibody. Using the currently available antibodies, our
data matched the previously published data where NKCC1
was shown to decrease with advancing age in naïve brains
(Supplementary Figure 4B). There were paradoxical trends
toward post-ischemic increase in NKCC1 levels in the ipsilateral
hemisphere at ≤48 h in this study (Supplementary Figure 5D),
as it was shown in a lesion study (Shimizu-Okabe, 2007). Similar
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 May 2015 | Volume 9 | Article 173
Kang et al. Neonatal seizures and Cl− co-transporters
FIGURE 5 | Age-dependent stroke injury. (A,B) Severity of the ischemic
injury evaluated at P18 in ligated-treated mice. Histopathological analyses
were performed on a series of coronal brain sections harvested at P18 for all
the ages investigated. Post-ischemic P7 brains were significantly less
vulnerable to necrotic infract injury compared to P10 and P12. Both
hemispheric and hippocampal atrophies associated with stroke injury were
significantly higher at P10 and P12. The stroke severities between P10 and
P12 were not significantly different. *p < 0.05.
findings have also been noted after neonatal hypoxia-ischemia
(Dai et al., 2005). These results indicate that neonatal ischemia
significantly alters the acute and sub-acute developmental
profiles of the adult-form chloride transporter KCC2; however,
NKCC1 developmental expression profiles remain relatively
unaltered or increased. While ischemia-related changes in
cellular populations were expected with the stroke lesions, both
co-transporters, KCC2 and NKCC1 would be similarly affected
by these changes at the three age groups evaluated (i.e., P7
group where no infarct lesions were seen at P18 vs. P10 and
P12 where they were commonly detected; see Figure 5). Both of
these co-transporters were evaluated in the same homogenized
brain samples, and KCC2 showed consistent downregulation at
6 to 48 h and recovery at 96 h. More importantly, the finding of
PB-resistance at P7 and the seizure-burden dependent efficacy
at P10 validates the P7-P10 CD1 mouse model of neonatal
ischemia reported here as a novel tool to test the efficacy of novel
anti-seizure pharmacotherapies in a clinically relevant model of
seizure induction.
Discussion
This study has several salient findings to report. (1) A newmouse
model of ischemic seizures that developed both primarily PB-
resistant seizures at P7 and PB-responsive seizures at P10. At
P10, PB-efficacy was dependent on the baseline seizure burden
(i.e., lower the seizure burden better the anti-seizure efficacy).
The acute seizures recorded in the first 3 h after initiation of
ischemia represented a status-like seizure burden state well
described for severities typically seen clinically in HIE (Boylan
and Pressler, 2013). (2) The age-dependent seizure susceptibility
after ischemia was significantly higher at P7 than both at
P10 and P12. This susceptibility may represent the underlying
age-dependent upregulation of KCC2 expression in maturing
brains. (3) An acute and significant post-ischemic KCC2
downregulation was detected at all ages tested. The post-ischemic
KCC2 downregulation catches up with the age-dependent
developmental increase, representing recovery from ischemic
insult within a few days. Therefore, ischemic injury significantly
modulates the developmental profile of the adult-form chloride
co-transporter KCC2, and thus dictates the efficacy of anti-
seizure medications that follow. (4) The NKCC1 antagonist,
BTN, failed to act as an adjunct in the new model for the primary
PB-resistant seizures. Additionally, BTN blunted the anti-seizure
efficacy of PB treatment at P10 with the follow-on treatment
paradigm, by aggravating the PB-subdued seizures. Hence,
NKCC1 blockage fails to rescue ischemic seizures regardless of
the anti-seizure efficacy of GABAA agonists which fail at P7 but
work at P10 and P12. (5) The sex-dependent seizure susceptibility
detected in P7 males may correlate with the developmental lag of
KCC2 expression in naïve males compared to females at that age.
This lag goes away with advancing age.
Neonatal seizures, especially those associated with ischemia,
are known to be transient in the neonatal period. HIE seizures
also show hours of increasing seizure burdens alternating with
quiet or low-seizing periods with crests and troughs during their
natural temporal progression (Low et al., 2014). How aggressively
we treat these transient seizures, which may be severe in some
cases, with drugs that may also alter the developmental profile
of an immature brain, is a subject of debate (Kossoff, 2011). The
exact time of onset of ischemia in neonates is rarely known, and
clinical seizures are detected a few hours to days later. This may
be due to either, a failure to detect the subtle early seizures since
most of the EEG seizures are non-clinical (Low et al., 2014), or
a slower paced evolution of the ischemic injury. The dynamics
of this evolution is however poorly understood and difficult to
quantitate clinically. Recent studies (Kwon et al., 2011) that have
tried to evaluate the issue are difficult to interpret with regards
to evolution because the baseline seizure burdens before onset
of treatment (Nash et al., 2011; Wusthoff et al., 2011) are rarely
known or quantifiable without EEG (Low et al., 2014). This
limitation in reported clinical studies persists due to the nature
of the disease and the lack of EEG data to accurately assess
pre-treatment seizure burdens of non-clinical seizures. Even
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FIGURE 6 | Developmental profile of KCC2 expression. (A) IHC for KCC2
in cortex as a function of postnatal age in naïve brains respectively (Scale bar
= 250 um) showed increased neuronal expression with age. (B) Western blot
quantitation of KCC2 expression as a function of postnatal age in naïve brains
(n = 3 for each age). Bar graphs show the co-transporter expression
normalized to actin expression of the same brains. (C) A significant
(Continued)
FIGURE 6 | Continued
sex-dependent lag of KCC2 expression was detected at P7 in naïve males
compared to age-matched naïve females (*p < 0.05), and this dimorphism
was not significant at older ages [M, male; F, female (n = 2 each at every age)].
Analyses for NKCC1 in the same brain samples are shown in
Supplementary Figures 4A–C.
so, PB-inefficacy as first-line treatment is now widely reported
(Painter, 1999; Sankar and Painter, 2005).
Intrinsic features of immature networks make GABAA-
based pharmacotherapy more difficult (Rakhade and Jensen,
2009). Following recurrent seizures, it has been shown that
intracellular chloride ions accumulate, making GABA strongly
excitatory (Khalilov et al., 1999; Khazipov et al., 2004; Khirug
et al., 2005; Nardou et al., 2011). Recent research has shown
that KCC2 downregulation following excitotoxic injury may
underlie these findings (Nabekura, 2002; Stein, 2004; Wake
et al., 2007; Gomes et al., 2012). Developmentally, NKCC1
mediates influx of chloride ions (Dzhala et al., 2010); however,
this chloride co-transporter is neither necessary nor sufficient,
as these shifts of GABA polarity also occur in NKCC1 KOs
(Nardou et al., 2011; Ben-Ari, 2012). Additionally, recent study
has identified two spice variants of NKCC1 in the human
brain, NKCC1a [1-27] and NKCC1b [1-27 (121)] (Morita
et al., 2014). NKCC1b is the dominant splice variant in human
brains, which shows an age-dependent upregulation (Kang et al.,
2011): Human Brain Transcriptome website. No reliable pan-
NKCC1 antibodies, capable of detecting both variants, are
currently available for reevaluating the NKCC1 data reported
here (Supplementary Figures 4, 5) or the similar published data
in animalmodels that may have only quantitatedNKCC1a, which
was shown to downregulate with advancing age (Plotkin et al.,
1997; Dzhala et al., 2005; Aronica, 2007). The activity-dependent
downregulation of KCC2 after NMDA-induced excitotoxicity
may lead to appearance of PB-resistance (Lee et al., 2011;
Puskarjov et al., 2014a), and pre-clinical animal models of
neonatal seizures that do not result in KCC2 downregulation
may not be relevant to ischemic seizures. Reports of KCC2
downregulation in the white-matter of premature babies with
white matter lesions support this hypothesis (Robinson et al.,
2010). Even in adult models of epilepsy (Deisz et al., 2011,
2014; Campbell et al., 2015), downregulation of KCC2 has
been detected in human cortices resected for refractory seizures
and in peritumoral neurons in mouse cortical slices, further
confirming that KCC2 is the key player in maintaining chloride
homeostasis in mature neurons. The expression profile of the
co-transporters in HIE brains remains unknown and has the
potential to add significant insights into pre-clinical animal
modeling (Kang and Kadam, 2014). Therefore, preventing KCC2
downregulation following injury may help delay the intracellular
chloride accumulation during repetitive ischemic seizures and
thus increase the efficacy of GABAA-agonists. The critical role of
KCC2 for chloride homeostasis and ultimately neuronal survival
has been well established in KCC2 knockout (KO) model of
in vitro and in vivo (Hubner, 2001; Pellegrino et al., 2011).
Knockout of isoforms, KCC2a and b are lethal in mice due
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FIGURE 7 | Seizure severity by age and sex. (A,B) Baseline seizure burdens pooled for ligated-control and ligated-treated pups showed an age-dependent
susceptibility for ischemic seizures that was significant in males but not in females. *p < 0.05
to respiratory failure, while KCC2b KO mice can survive up
to P17, with frequent and severe spontaneous seizures (Woo,
2002; Blaesse et al., 2009). In addition, the now known role
of KCC2 in spine development (Li et al., 2007) and cortical
interneuron migration (Bortone and Polleux, 2009) may indicate
that post-excitotoxic downregulation of KCC2 may underlie the
development of long-term sequelae like cognitive and behavioral
deficits. In contrast, the NKCC1 KO mouse does not have
spontaneous seizures, is non-lethal but deaf (Flagella et al., 1999).
Since our study showed a strong correlation between the severity
of the early untreated ischemic seizures and PB-efficacy as a
function of age, this animal model of PB-resistant seizures would
be a useful tool to test this hypothesis further.
Using physiologic techniques, the intracellular chloride shift
has been shown to be primarily due to the downregulation
and internalization of the chloride exporter KCC2 (Lee et al.,
2010, 2011; Nardou et al., 2011). It has been shown that KCC2
downregulation occurs immediately within minutes after an
excitotoxic injury (Rivera et al., 2004; Puskarjov et al., 2012).
This finding complements data from other studies showing that
this co-transporter is highly sensitive to serine and tyrosine
phosphorylation and seizures that control its turnover (Lee
et al., 2010, 2011; Kahle et al., 2013). The diuretic NKCC1
antagonist, BTN, has been proposed as a novel anti-seizure
medication (Dzhala et al., 2008) and was the basis of a current
clinical trial (NEMO, FP7-EU clinical trial: http://www.nemo-
europe.com/ and ClinicalTrials.gov; NCT00830531); however,
BTN blocks seizures in some but not all models of seizures
(Kilb et al., 2007). Even with a pre-treatment protocol used
in a chemoconvulsant model in neonatal rats, studies have
shown an age-dependent specificity of the lack of efficacy of
BTN (Mares, 2009) where higher doses actually decreased the
latency to generalized seizures in the older pups (i.e., P12).
With the recent reports of the termination of the European
clinical trial reporting BTN-inefficacy for HIE seizures associated
with ototoxicity (Pressler et al., 2015), testing higher doses of
BTN seems counterproductive. The results of our experiments
using a clinically relevant post-treatment protocol support these
reports. In the immature brain, it is possible that the very early
seizures, which occur before a significant KCC2 downregulation
has begun, may be efficaciously blocked by BTN alone or as
an adjunct treatment after PB (Nardou et al., 2009, 2011).
In addition, BTN as an adjunct treatment to PB may work
efficaciously in neonatal seizures that are not associated with
KCC2 downregulation (Cleary et al., 2013). However, after
recurrent seizures and KCC2 degradation (Puskarjov et al., 2015),
GABA strongly excites neurons in the immature brain, and drugs
like PB that act as GABAA agonists fail to act. Similarly, our
findings suggest that PB-efficacy is dependent on the baseline
seizure burdens specifically at P10 in our model. Our studies
show that BTN fails to improve PB-efficacy when given as a
follow-on treatment at P7. Our results also show that BTN can
blunt PB-subdued seizures at P10. The BTN aggravation in our
study following PB-efficacy may not be detected clinically, since
BTN would not be administered to a patient whose seizures
have responded well to PB. However, this finding is of scientific
significance and deserves further evaluation to understand the
underlying mechanism.
In general, the use of BTN in critically ill patients
requires caution. Blocking NKCC1 function in the brain
during development may interfere with critical circuit formation
(Wang and Kriegstein, 2010). BTN non-specificity as a NKCC1
antagonist and its ability to also block KCC2 at higher doses
(Puskarjov et al., 2014b) should be an additional concern in
a seizing brain. The associated ototoxicity detected in the
NEMO trial associated with the expression of the same NKCC1
isoform in the inner hair cells, should raise caution for all
neonatologists who use BTN for its approved use as a diuretic
(Pressler et al., 2015). In a model of hypoxic seizures, the
maximum concentration of BTN in the brain was estimated
to be 1.2 ng/ml following an acute dose of BTN injected IP at
0.3mg/kg (Cleary et al., 2013). Recent review also discusses the
various reasons for the low bioavailability of BTN in brain, a
significant caveat to this line of pharmacotherapy (Puskarjov
et al., 2014b). Although BTN prodrugs designed for better
brain bioavailability now exist, the anti-seizure efficacies of those
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FIGURE 8 | Post-ischemic KCC2 downregulation. Western blot
quantification of post-ligation expression of KCC2 in P7, P10, and P12 ligated
pups at acute and sub-acute time-points after ischemia (n = 3 each) in ipsi-
and contralateral (i.e., injured and uninjured hemispheres, respectively)
hemispheres; (A) At P7, the significant downregulation of KCC2 detected
within 6–8 h of ligation (*p = 0.004) showed a complete recovery by 96 h.
(Continued)
FIGURE 8 | Continued
(B) At P10, KCC2 downregulation showed the same trend as at P7 at 48 h.
(C) P12 pups showed a significant downregulation of KCC2 at 24 h
(*p < 0.02). (D) Scatter plot of KCC2 expression levels, normalized to actin
and shown as the percent of levels in their respective contralateral uninjured
hemispheres. All acute time-points (6–48 h) were pooled from all three age
groups (n = 13). Data show that ischemia in the CD1 mice results in an acute
KCC2 downregulation in the ischemic injured hemispheres with approximately
45.35% reduction in mean expression (pairwise t-test, p = 0.0002;
contralateral control is 100%, which is represented as a dotted gray line as a
ratio of 1).
BTN prodrugs were recently investigated and show no clear
effect (Tollner et al., 2015). Additionally, the issue of side-
effects such as diuresis and ototoxicity remain. The phenomenon
of BTN aggravation of seizures reported here occurred only
after PB was efficacious in subduing the ischemic seizures
(Supplementary Figures 3,6) in an immature brain where KCC2
is already significantly downregulated. In addition to the acute
side-effects, BTN has also been shown to result in deleterious
long-term effects. A significant increase in the percentage of rats
having spontaneous seizures has been reported in response to the
acute administration of BTN following PB in a pilocarpine model
of temporal epilepsy (Brandt et al., 2010). BTNmay also attenuate
the seizure-induced activation of HPA by blocking NKCC1 in
periventricular neurons (O’Toole et al., 2014). However, this
study was done in adult rodents, and the effect of BTN on
HPA axis in immature brains is not known. Overall, further
work is required to understand the potential cause of post-BTN
aggravation of seizures reported in this model.
Early and effective treatment of neonatal seizures following
excitotoxic insults is of course the gold standard for management;
but early and efficacious treatment is not always attainable.
Inability to detect the exact onset of ischemia, failure to detect
subtle neonatal seizures, and the likelihood of preceding in utero
ischemic insults may lead to the early KCC2 downregulation
and a lag in developmental profile that may underlie the
increased seizure susceptibility and PB-resistance of the first
detected seizures. Ischemia in the developing brain likely
alters the expression profile of a multitude of factors that
modulate transmembrane ionic gradients. This study shows
that the pathology underlying the occurrence of neonatal
seizures may dictate drug responses. Current clinical trials for
BTN were initiated based on earlier reports of BTN-efficacy
from non-ischemic models that may depend on the stable
KCC2 expression following the initial insult. However, our data
show that KCC2 downregulation, beginning in utero following
ischemia or possibly infection/inflammation, may make early
interventions with BTN futile. In conditions where KCC2 is
already downregulated before birth or lagging in the age-
dependent upregulation (Morita et al., 2014), blocking Cl−
import through NKCC1 cannot compensate for the role of KCC2
as a Cl− extruder. Additionally, we do not clearly understand the
BTN-induced aggravation of seizures detected in our study that
was also differentially modulated by sex. BTN half-life in rodents
is short and at∼ 30min (Cleary et al., 2013), clearly less than the
1 h of seizure burden quantitated in this study. BTN aggravation,
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when noted, began within 5–10min of the treatment and lasted
throughout the 1 h of recording (Supplementary Figures 3, 6).
Recent evidence of estradiol modulation of NKCC1 (Nugent
et al., 2012) shows that many details of this process and its sex-
dependent modulation remain to be understood. The overall
age-dependent susceptibility of males to ischemic seizures in
this study and the additional window period of a lag in KCC2
development in naïve brains may add to the accumulating data
on male susceptibility to developmental injury and differential
effects of neonatal treatments by sex (Johnston and Hagberg,
2007).
In conclusion, this study highlights the variability of drug
responses in animal models based on the mechanism by which
the seizures are induced. For BTN, thesemodel-specific outcomes
have already been reported to be very variable (Kilb et al.,
2007). Dose-dependent efficacy detected for higher doses of BTN
(Mazarati et al., 2009) has been shown to suppress neonatal
kindling when given as a pre-treatment protocol and has been
proposed as a reason behind the failure of lower dose regimens
reported in other models. However, pre-treatment protocols have
also resulted in an aggravation of seizure onset latencies with
higher doses in immature rats using chemoconvulsants (Mares,
2009). Additionally, BTN failed to work at P7 in that study
which highlights the age-dependency for its efficacy. The findings
of our study suggest that when KCC2 levels remain unaltered
or become enhanced after kindling, such protocols may not
be translationally relevant to the HIE patients being recruited
in the current clinical trials where ischemia is the prominent
underlying cause. This hypothesis is now supported by outcomes
reported in the recently published NEMO study (Pressler et al.,
2015). The same caveat would apply to the translational value
for the BTN pre-treatment paradigms that alter the chloride
gradients in the naïve brains prior to insult induction in a dose-
dependent manner. The variable effects of BTN reported in
recent literature and in this current study, highlight the need
for further translational research using BTN (Vanhatalo et al.,
2009). A recent study, Cleary et al. has reported beneficial dose-
dependent effects of PB+BTN pre-treatment in a rat model of
hypoxic neonatal seizures (Cleary et al., 2013). Since they also
reported a significant upregulation of KCC2 in hippocampus
on the day of assessment of BTN treatment efficacy, these data
strongly suggest that KCC2 downregulation after ischemia may
be a major player in the development of PB-resistance. BTN
efficacies were shown to be age- and sex-specific even within the
relatively narrow age range investigated in this study. None of the
pre-treatment studies noted above examined sex differences. Our
results also indicate that neonatal stroke/seizures left undetected
or untreated for extended periods of time alter the acute and
sub-acute developmental profiles of the adult-form chloride co-
transporter KCC2 such that the later seizures may become
resistant to treatment with the conventional anticonvulsants
that act as GABAA agonists (Puskarjov et al., 2014b, 2015).
Prolonged seizures are also known to alter GABAR such that it
reduces the efficacy of AEDs (Sankar et al., 2002; Jones-Davis
andMacdonald, 2003). In neonates, the transient downregulation
and the developmental lag in the KCC2 expression profile may
additionally result in chronic alteration of the way the immature
brain is getting wired within that critical developmental window
(Lombroso, 2007). This study shows that a novel focus on
preventing KCC2 downregulation or enhancing KCC2 function
following neonatal insults may be critical in guiding future
approaches for treating PB-resistant seizures in neonates.
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Supplementary Figure 1 | Representative electrographic seizure traces.
EEG traces (panels 1, 2) of visually identified electrographic seizures (associated
video behavioral grades 2 and 4). Raw EEG traces are followed by high and low
frequency band pass filtered data. Seizure activity in 13–60Hz range did not occur
during non-ictal events (panel 3) associated with movement artifacts or jittery
walking activity in non-seizing pups. These data highlight the importance of EEG
as the gold standard for seizure burden assessment in the mouse model of
neonatal seizures. The behavioral correlates alone were not a reliable measure in
evaluating the total seizure burden in pups.
Supplementary Figure 2 | Representative time-compressed plot (1 h) of
EEG traces recorded from P7 pups and an additional expanded time scale
of a 5min EEG trace from the same recording. (A) P7 sham-operated control
that was exposed to the same amount of isoflurane anesthesia as other ligated
pups; (B,C) P7 Representative male and female pup showing higher baseline
seizure susceptibility for males following ischemia.
Supplementary Figure 3 | Representative time-compressed plot (1 h) of
EEG traces recorded from P7 vs. P10 ligated pups (time-course schematic
of drug administration shown at the top). An additional expanded time scale
of a 5min EEG trace from the same recordings show individual ictal events. Both
EEG traces for P7 and P10 were selected from the median of the each cohort.
Supplementary Figure 4 | Developmental profile of NKCC1 expression.
(A,B) Western blot quantification of post-ligation expression of NKCC1 in P7, P10,
and P12 ligated pups at acute and sub-acute time-points after ischemia (n = 3
each) in ipsi- and contralateral (i.e., injured and uninjured hemispheres,
respectively) hemispheres; (C) No lag in the NKCC1 expression was detected in
the male vs. female pups at P7 or at later ages in the naïve brains [M, male; F,
female (n = 2 each at every age)].
Supplementary Figure 5 | Post-ischemic NKCC1 expression. Western blot
quantification of post-ligation expression of NKCC1 in P7, P10, and P12 seizing
pups at different acute and sub-acute time-points after ligation in bilateral
hemispheres (n = 3 each) (A) At P7, NKCC1 remained unaltered at 6–8 h with
significant increase in expression at 96 h (p = 0.049). (B) At P10, NKCC1
expression at 48 h post-ligation did not change significantly (p = 0.06). (C) NKCC1
remained unaltered in the same brains of P12. (D) Scatterplot of NKCC1
expression normalized to contralateral uninjured hemisphere. n = 13 in Figure 8D
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and Supplementary Figure 5D (n pooled for time-points 6–48 h post-ischemia).
Please refer to Figure 8D for further details.
Supplementary Figure 6 | Representative frequency histogram of ictal
events after PB+BTN treatment at P7, P10, and P12. Frequency histograms
of EEG identified ictal events depicted as 1 h slots for the 3 h recording period (top
to bottom panel) for both P7 and P10 ligated-control and ligated-treated pups.
The pups represent mean seizing rates for the data set depicted in Figure 2. The
ictal event distribution graphs represent the lack of seizure clustering during the
3 h recording period for the model. The post-BTN 3rd h recording in a P10 pup
also represents the age-specific BTN-induced blunt of PB-subdued seizures in the
3rd h of recording. BTN pharmacokinetics are known to be short (≤30min; Cleary
et al., 2013), but the BTN aggravation persisted for the entire 1 h duration of EEG
seizure burden.
Supplementary Video 1 | Close up view of convulsive grade 3 behavior
with clockwise circling toward the side of ischemia and tonic posturing of
right forearm. This behavior was never recorded in non-seizing or naïve
age-matched pups.
Supplementary Video 2 | Close up view of convulsive grade 5 behavior in a
ligated pup.
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